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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.05.004Background: The clinical results of lung transplantation and concomitant cardiac
surgery are unclear. The effect of cardiopulmonary bypass on the pulmonary
allograft is controversial, and the effect of cardiac arrest and cardiac surgery in this
setting is unknown. Our aim was to review the operative results and long-term
survival in this group of patients.
Methods: A retrospective review of all lung transplantations between 1988 and 2003
was performed. Patients who had concomitant cardiac surgery during lung trans-
plantation were compared with those who underwent lung transplantation alone.
The variables analyzed included allograft ischemic times, use of cardiopulmonary
bypass, early graft dysfunction, postoperative morbidity, survival, length of me-
chanical ventilation, length of stay in the intensive care unit, and overall hospital
stay.
Results: During this period, 35 of 700 lung transplant recipients (15 single and 20
bilateral transplantations) underwent concomitant cardiac surgery. The cardiac
procedures were for patent foramen ovale (n  18), atrial septal defect (n  9),
ventricular septal defect (n  2), coronary bypass (n  4), and “other” (n  2).
Allograft ischemic time, use of extracorporeal membrane oxygenation, length of
hospital stay, operative mortality, and survival were not significantly different
between the 2 groups. Ventilator time and intensive care unit stay were longer in the
cardiac surgery group.
Conclusions: Cardiac surgery at the time of lung transplantation can be performed
with acceptable morbidity and mortality. The immediate and long-term survival in
these patients is similar to that of other lung transplant recipients. Lung transplan-
tation should continue to be offered to patients with normal ventricular function who
require concomitant limited cardiac surgery.
Over the past two decades, lung transplantation has become an effectivetreatment for a variety of end-stage lung diseases. Advances in surgicaltechniques, preservation of ischemic allografts, immunosuppression, and
management of infectious complications have steadily improved the results of lung
transplantation. Nonetheless, organ donor shortage and long waiting lists have
precluded patients with other serious comorbidities to be considered for lung
transplantation. These patients traditionally have been denied lung transplantation to
maximize favorable patient outcomes.
Comorbidity from underlying cardiac disease is one such factor that has poten-
tially prohibitive surgical risks and poses a difficult clinical challenge. Although use
of cardiopulmonary bypass (CPB) during lung transplantation might allow for
controlled reperfusion of the lung, it also can have several potential adverse
sequelae, including increased bleeding, increased cytokine expression and activation
of the complement system, and endothelial damage. Addition of cardiac arrest, with
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TXits known increase in the inflammatory response, can further
increase morbidity and mortality after lung transplanta-
tion.1,2 We reviewed our experience in patients who under-
went a concomitant cardiac procedure during lung trans-
plantation to determine the morbidity and early and late
mortality associated with this approach.
Methods
Patients
A retrospective review of all lung transplantations at our institution
between January 1988 and August 2003 was performed. Of the
700 patients who underwent lung transplantation, 35 (0.5%) were
identified who underwent concomitant lung transplantation and
cardiac surgery. Background characteristics of the patients who
underwent concomitant procedures in comparison with the patients
who underwent isolated lung transplantation are as shown in Table
1.
Operative Procedure
A total of 15 unilateral and 20 bilateral lung transplantations were
performed in the patients who had a concomitant cardiovascular
procedure. The majority of cardiac procedures were for repair of
congenital intracardiac septal defects (Table 2). All the procedures
were done with CPB, and the cardiac procedure was performed
before the implantation of the lungs. CPB was continued during
lung implantation. Need for extracorporeal membrane oxygenation
(ECMO) was clinically determined intraoperatively if, after all
standard maneuvers for alveolar recruitment, optimization of ven-
TABLE 1. Univariate analysis of preoperative characterist
Lung transplantation
only (n  665)
Age (y) 48 12
Sex (female) 335 (50.3%)
Diagnosis
COPD 385 (57.9%)
Cystic fibrosis 113 (17.0%)
Pulmonary hypertension 37 (5.6%)
IPF 76 (11.4%)
Other 54 (8.1%)
Waiting time (d) 551 372
COPD, Chronic obstructive pulmonary disease; IPF, idiopathic pulmonary
TABLE 2. Description of the type of elective concomitant
cardiac surgery performed
Type of cardiac surgery performed N
Patent foramen ovale closure 18
Atrial septal defect repair 9
Ventricular septal defect repair 2
Coronary artery bypass (single vessel) 4
Pulmonary artery aneurysmectomy
with reconstruction
1Replacement of ascending aorta 1
860 The Journal of Thoracic and Cardiovascular Surgery ● Septtilation and administration of nitric oxide had failed and there was
evidence of significant graft dysfunction manifested by persis-
tently low PaO2. Usually, there were several problems addressed
by the use of ECMO: hypoxemia, hypercarbia, respiratory acido-
sis, and stiff lung mechanics with very high airway pressures.
There were no standard criteria for use of ECMO on any one of
these factors, but a clinical impression was made on the basis of all
of them simultaneously.
Morbidity, Mortality, and Long-Term Survival
Morbidity data were collected from our lung transplantation data-
base that documents all adverse outcomes on the basis of prospec-
tive data collection from the patient’s clinical records. Early graft
dysfunction was defined as a PaO2/inspired fraction of oxygen of
150 or less on initial or 24-hour arterial blood gas measurement.
Acute renal failure was defined as doubling of the serum creatinine
concentration compared with baseline values without the need for
renal replacement therapy. Coagulopathy was defined as persistent
abnormalities in the partial prothrombin time or prothrombin time,
a platelet count of less than 100,000/mm3, or both, in the presence
of active bleeding requiring transfusions. Sepsis was defined as a
persistent increase in the white blood cell count and concomitant
hypotension requiring treatment with vasopressors and antibiotics,
with or without associated fever. Finally, myocardial infarction
was based on enzymatic increases of creatine phosphokinase or
troponin above normal values, with or without associated electro-
cardiographic changes.
The cohort that underwent the concomitant procedures was
compared with the rest of the patients who had isolated lung
transplantation. The variables analyzed included ischemic times,
length of mechanical ventilation, length of stay in the intensive
care unit (ICU), length of stay in the hospital, and overall hospital
mortality. Long-term survival between the 2 groups was also
analyzed.
This study was approved by the Institutional Review Board of
Washington University School of Medicine.
Statistical Analysis
Descriptive statistics were expressed as means  standard devia-
tion unless otherwise specified. Categorical data were expressed as
counts and proportions. Comparisons were done with unpaired,
etween groups
Concomitant cardiac
surgery (n  35) P value
40  12 .001
19 (54.3%) .730
.001
4 (11.4%)
2 (5.7%)
26 (74.3%)
3 (8.6%)
0
536 337 .816
is.ics b2-tailed t tests for means of normally distributed continuous vari-
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or 2 tests were used to analyze differences among the categorical
data. Kaplan-Meier estimates were used to depict survival. Cox
multivariate proportional hazards regression was used to adjust for
confounding variables that were found to be different between the
groups in univariate testing to further examine survival after trans-
plantation. All data analysis was performed with SPSS (SPSS 11.0
for Windows; SPSS Inc, Chicago, Ill).
Results
Univariate Analysis
The mean age of patients undergoing combined cardiac
procedures and lung transplantation was lower than that of
patients who underwent isolated lung transplantation (40 
12 vs 48  12 years, P  .001). The most common
indication for transplantation was chronic obstructive pul-
monary disease in 57.9% of patients undergoing isolated
lung transplantations, whereas 74.3% of the patients had
pulmonary hypertension in the cohort who had the com-
bined procedure (P  .001). In the pulmonary hypertension
group, primary pulmonary hypertension was present in 14
of the 26 patients, all of whom had patent foramen ovale
(PFO) repair during lung transplantation. In the remaining
12 patients, pulmonary hypertension was associated with a
preexisting congenital cardiac anomaly. Other preoperative
factors, such as sex and time spent on the waiting list, were
not significantly different between the 2 groups (Table 1).
Of the patients who underwent combined procedures, 20
(57.1%) of 35 had bilateral lung transplantations in com-
parison with the other cohort in which the large majority of
the patients underwent bilateral lung transplantations (505/
665 [75.9%]). The mean allograft ischemic time for both
groups of patients was not significantly different (285.8 
66.5 minutes for the isolated lung transplantation group vs
296.8  70.7 minutes for the combined group, P  .342).
Although CPB was used in all the patients undergoing
concomitant cardiac procedures, only 20% of the cases of
isolated lung transplantation required use of CPB. The use
of ECMO and in-hospital mortality were higher in the
patients with the combined procedures compared with those
TABLE 3. Univariate analysis of postoperative outcomes b
Lung transplantation
only (n  665)
Bilateral transplantation 504 (75.9%)
Ischemic time (min) 285.8 66.5
Use of CPB 123 (18.4%)
ECMO required 17 (2.6%)
Mortality 49 (7.4%)
CPB, Cardiopulmonary bypass; ECMO, extracorporeal membrane oxygenaundergoing isolated lung transplantations (Table 3).
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There were 4 (11.4%) in-hospital deaths in the patients who
underwent a combined procedure. Two died of primary
graft failure, 1 died of a cerebrovascular accident, and 1
died of intraoperative hemorrhage. The patient who died of
intraoperative hemorrhage had undergone a prior repair of
an aortic coarctation with significant adhesions related to his
previous operation. During dissection, an inadvertent tear in
the ascending aorta necessitated urgent establishment of
CPB for replacement of the ascending aorta.
The patients undergoing combined procedures had a
significantly longer requirement for postoperative mechan-
ical ventilation, with a median time of 5 days on the ven-
tilator, compared with the patients undergoing isolated lung
transplantations, who had a median time of 2 days (P 
.001). Patients undergoing cardiac surgery also had a longer
stay in the ICU compared with the other group, with a
median stay in the ICU of 6 days compared with 3 days (P
 .001). However, overall length of stay in the hospital was
similar between the 2 cohorts (P  .355, Figure 1).
Table 4 lists postoperative complications in patients un-
dergoing concomitant cardiac surgery. The most common
complication was supraventricular arrhythmias (37.1%),
en groups
Concomitant cardiac
surgery (n  35) P value
21 (57.1%) .032
296.8 70.7 .342
35 (100.0%) .001
3 (8.6%) .073
4 (11.4%) .328etweFigure 1. Posttransplantation hospitalization.
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for bleeding was required in 8 (22.9%) patients.
Long-Term Survival
The survival in the patients who underwent isolated lung
transplantations was 84.9% at 1 year, 72.3% at 3 years, and
57.0% at 5 years. This was not significantly different from
the survival in the cohort that had concomitant cardiac
surgery and lung transplantation, which showed a survival
of 77.1% at 1 year, 66.7% at 3 years, and 54.2% at 5 years
(Figure 2). In a Cox multivariate analysis, adjusting for age
and diagnosis, concomitant cardiac surgery was not found to
be a predictor for decreased survival. To account for the
large number of patients who had closure of a PFO as the
primary cardiac operation, we repeated the survival analysis
by dividing the concomitant cardiac surgery group into
those who had closure of a PFO and those who had other
operations. There were no differences in survival at 5 years
among the various subgroups: 56.9%, 48.7%, and 62.5% for
isolated lung transplantation, other concomitant cardiac sur-
gery, and concomitant PFO closure, respectively (P 
.330). Furthermore, analyzing the survival of patients with
concomitant cardiac surgery and lung transplantations on
the basis of 2 separate eras (before 1995 and after 1995) to
account for the shift in our practice to perform double-lung
transplantations failed to identify any survival difference
between the 2 groups: 61.1% at 5 years for those undergoing
transplantation before 1995 and 44.6% at 5 years for those
undergoing transplantation from 1995 and beyond (P 
.472).
Discussion
Lung transplantation has become an accepted treatment for
end-stage lung disease over the past 2 decades. Concomitant
cardiac surgery during lung transplantation might increase
the perioperative morbidity associated with this procedure.
Our data suggest that patients who require limited cardiac
surgery at the time of lung transplantation have an accept-
able morbidity and mortality, with early and long-term
TABLE 4. Description of the postoperative morbidity in the
concomitant cardiac surgery group
Hospital morbidity N (%)
Dysrhythmia 13 (37.1%)
Early graft dysfunction 10 (28.6%)
Acute renal failure 8 (22.9%)
Reexploration for bleeding 8 (22.9%)
Required reintubation 7 (20.0%)
Coagulopathy 5 (14.3%)
Sepsis 2 (5.7%)
Myocardial infarction 2 (5.7%)survival similar to that of patients undergoing isolated lung
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offered to patients with normal ventricular function who
require concomitant limited cardiac surgery.
Previous studies have reported mixed results with use of
CPB during lung transplantation.2-5 Indications for use of
CPB generally depend on the presence of significant pul-
monary hypertension, the ability to tolerate single-lung ven-
tilation, and other intraoperative factors.6 Concerns regard-
ing the use of CPB include the need for heparinization and
the increased risk of bleeding and transfusion requirements.
In addition, other recognizable disadvantages include the
upregulation of the inflammatory response and the possibil-
ity of increased permeability of the pulmonary capillary
bed. Despite these limitations, several studies suggest that
CPB might have immunomodulating effects and actually
improves outcomes in HLA-mismatched patients.4 The ad-
dition of a cardiac surgical procedure with use of CPB
might further potentiate the inflammatory response.7,8
Given these concerns, the purpose of this retrospective
study was to determine whether addition of a cardiac sur-
gical procedure to an already complex operation would
increase the morbidity and mortality of lung transplantation.
In this group we found a longer duration of ventilatory
support and ICU stay, a 23% incidence of reexploration for
bleeding, and a 29% incidence of early graft dysfunction.
The overall incidence of primary graft dysfunction at our
institution is 22%, and the incidence is highest in the pa-
tients who undergo transplantation for primary pulmonary
hypertension.9 In addition, longer duration of ventilatory
support and ICU stay is more common in this subgroup.9
Given that 74% of the patients who had cardiac surgery had
underlying primary pulmonary hypertension as the reason
for lung transplantation, our results are not surprising. How-
ever, previous reports on patients undergoing bilateral lung
Figure 2. Kaplan-Meier survival after lung transplantation strat-
ified by those who underwent lung transplantation only and those
who underwent a concomitant cardiac surgical procedure with
the lung transplantation.transplantation with CPB have shown an increased inci-
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and late mortality were not different, which is similar to our
data. Similarly, Pigula and colleagues10 reported their ex-
perience with 30 patients, of which 23 had a combined
procedure and 7 had a history of cardiac procedures for
repair of congenital anomalies. In their experience, mortal-
ity was 23% (7/30), and the long-term survival of the
patients who survived was similar to that of the group that
underwent heart-lung transplantation for congenital heart
disease. The authors concluded that by doing the combined
procedure of fixing the congenital heart disease and lung
transplantation, they expanded the donor pool because oth-
erwise these patients would require combined heart-lung
transplantation. This approach has been adopted in the pe-
diatric population; however, it has not been used in the adult
patient with congenital heart disease.11
Coronary artery disease was previously considered an
absolute contraindication for lung transplantation. The true
incidence of coronary artery disease in the patients consid-
ered for lung transplantation is not known; however, risk
factors such as smoking are common in patients with end-
stage lung disease and can lead to a significant increase in
the incidence of coronary artery disease in potential lung
recipients. As a result, cardiac catheterization is routinely
performed at our center as part of evaluation for consider-
ation of lung transplantation.
Recently, we have performed transplantations in patients
with normal ventricular function and limited coronary artery
disease with good results and no complications related to
the coronary artery disease.12 Although all our patients
underwent a single-vessel bypass, the group at Duke has
reported good outcomes in patients who underwent 2- and
3-vessel bypass.13
The primary limitation of this study, as with most un-
controlled analyses, is the selection bias for patients who
underwent cardiac surgery during lung transplantation.
Clearly, data on patients who were refused because of more
complex anatomy or other cardiac comorbidities were not
available. Despite the small sample size, we conclude that
The Journal of Thoracifor patients with adequate ventricular reserve, cardiac sur-
gery can be performed during lung transplantation with
acceptable morbidity and mortality and good long-term
survival.
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